CG Oncology, Inc. to Post FY2024 Earnings of ($1.77) Per Share, Lifesci Capital Forecasts (NASDAQ:CGON)

CG Oncology, Inc. (NASDAQ:CGON) – Stock analysts at Lifesci Capital dropped their FY2024 EPS estimates for shares of CG Oncology in a note issued to investors on Tuesday, April 23rd. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($1.77) per share for the year, down from their previous estimate of ($1.75). The consensus estimate for CG Oncology’s current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for CG Oncology’s FY2025 earnings at ($2.11) EPS and FY2026 earnings at ($1.22) EPS.

Several other research analysts have also recently commented on CGON. The Goldman Sachs Group assumed coverage on CG Oncology in a research note on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 price target on the stock. Morgan Stanley started coverage on CG Oncology in a research note on Tuesday, February 20th. They set an “overweight” rating and a $55.00 target price for the company. Cantor Fitzgerald started coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They issued an “overweight” rating and a $75.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a research note on Thursday, April 4th.

CG Oncology Stock Performance

CGON opened at $41.00 on Thursday. The firm’s 50 day moving average price is $40.32. CG Oncology has a 52-week low of $28.55 and a 52-week high of $50.23.

Insider Transactions at CG Oncology

In other news, major shareholder Decheng Capital Global Life Sc bought 400,000 shares of the business’s stock in a transaction on Monday, January 29th. The shares were bought at an average cost of $19.00 per share, with a total value of $7,600,000.00. Following the purchase, the insider now directly owns 400,000 shares in the company, valued at $7,600,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other CG Oncology news, major shareholder Decheng Capital Global Life Sc bought 400,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was bought at an average cost of $19.00 per share, with a total value of $7,600,000.00. Following the completion of the transaction, the insider now directly owns 400,000 shares of the company’s stock, valued at approximately $7,600,000. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Corleen M. Roche bought 2,000 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were bought at an average cost of $19.00 per share, with a total value of $38,000.00. Following the transaction, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at $38,000. The disclosure for this purchase can be found here. Insiders purchased a total of 666,472 shares of company stock valued at $12,662,968 in the last three months.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.